Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154788 | 0.87 | KMT2A (0.40) | MEN1KMT2AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL18154731 | 0.85 | MAPT (0.56) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL18154795 | 0.84 | NAMPT (0.38) | MEN1KMT2AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL18154664 | 0.80 | KMT2A (0.43) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30353164 | 0.78 | PIK3C3 (0.42) | KMT2AMAPTLMNAALDH1A1RAB9A | |
| SCHEMBL18154717 | 0.78 | PIK3C3 (0.42) | KMT2AMAPTLMNAALDH1A1RAB9A | |
| SCHEMBL18154809 | 0.76 | ALDH1A1 (0.39) | MAPTL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL30353158 | 0.76 | ALDH1A1 (0.39) | MAPTL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18154704 | 0.75 | ALDH1A1 (0.34) | MAPTL3MBTL1LMNAALDH1A1HTT | |
| SCHEMBL18154756 | 0.74 | CYP2C19 (0.41) | MAPTL3MBTL1SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3283482-A1 | PLK4 INHIBITORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166604-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | MEN1 3546/4885KMT2A 1059/4885MAPT 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.